Open main menu

kogic.kr β

Changes

Affymetrix

79 bytes removed, 16:24, 18 August 2010
no edit summary
<h2><span class="mw-headline">Description of Product</span></h2>
<div class="thumb tright">
<div class="thumbinner" style="WIDTH: 152px" class="thumbinner"><img class="thumbimage" heightborder="1360" alt="Example of two Affymetrix chips" width="150" height="136" src="http://upload.wikimedia.org/wikipedia/commons/thumb/2/22/Affymetrix-microarray.jpg/150px-Affymetrix-microarray.jpg" width="150" border="0" />
<div class="thumbcaption">
<div class="magnify" style="FLOAT: right" class="magnify"><img heightalt="" width="1115" altheight="11" src="http://en.wikipedia.org/skins-1.5/common/images/magnify-clip.png" width="15" /></div>
Example of two Affymetrix chips</div>
</div>
<p>Competitors in the DNA Microarray business include Illumina, GE Healthcare, Ocimum Biosolutions, Applied Biosystems, Beckman Coulter, Eppendorf Biochip Systems[1], and Agilent. There are also various inexpensive plastic-based technologies under development in small companies and laboratories around the world. It has been widely speculated that mass-produced plastic chips can be produced at lower prices than Affymetrix's quartz chips.</p>
<p>The company also manufactures machinery for high speed analysis of biological samples. List prices for the newest DNA arrayers, which prepare and place samples onto chips, are around $250,000 each. Scanners which read the results from the chip list from $150,000 for complete starter systems to $325,000 for high-throughput systems. Substantially lower retail prices have been seen in the market.</p>
<p>The business model of Affymetrix is based on these sources for revenue: consumables; instruments; subscription, service, license; royalty; and sales to Perlegen Sciences. Affymetrix currently controls 82% of the DNA microarray market<sup class="noprint Template-Fact"><span style="WHITE-SPACE: nowrap" title="This claim needs references to reliable sources since February 2007" style="WHITE-SPACE: nowrap">[<em>citation needed</em>]</span></sup> in terms of sales.</p>[http://www.california-liability-insurance.com/ General Liability Insurance CA]
<p>Affymetrix has established a licensing program to make its intellectual property accessible to stimulate the broad commercialization of genome analysis technologies. Licensing fees have offset weak product sales in Q3-2006. They have several collaboration relationships with other companies that utilize their patented GeneChip technology.</p>
<p>Currently Affymetrix is fighting a patent infringement lawsuit against Illumina, alleging the infringement of six Affymetrix patents. A pre-trial hearing favors Affymetrix, but the trial is not until May 2007.</p>
<h2><span class="mw-headline">References</span></h2>
<ul>
<li><a class="external text" title="http://www.affymetrix.com/corporate/history/index.affx" rel="nofollow" href="http://www.affymetrix.com/corporate/history/index.affx" rel="nofollow">Affymetrix - Corporate History</a>. Affymetrix. Retrieved on <a title="2006" href="http://en.wikipedia.org/wiki/2006">2006</a>-<a title="November 20" href="http://en.wikipedia.org/wiki/November_20">11-20</a>. <em>Note: reference includes all child pages and documents of this page, inclusive. There is some contradiction in specific details of the founding of Affymetrix among documents found here.</em> </li>
</ul>
<!--